Sodium-glucose co-transport 2 inhibitor decreases fasting plasma glucose level in impaired fasting glucose but not in normal glucose tolerance subjects / 中华内分泌代谢杂志

ABSTRACT

Renal sodium-glucose co-transport 2 inhibitor (SGLT2i) can reduce fasting plasma glucose (FPG) in patients with type 2 diabetes mellitus,but its effect on FPG and β-cell function in impaired fasting glucose (IFG) is unclear. The current article is the Chinses translation of an article entitled as"Inhibition of Renal Sodium-Glucose Co-Transport with Empagliflozin Lowers Fasting Plasma Glucose and Improves Beta Cell Function in Subjects With Impaired Fasting Glucose",which was published in "Diabetes" in September [Diabetes, 2017, 662495-2502],with the consent of"Diabetes". Eight subjects with IFG and eight subjects with normal FPG(NFG) were included in the study. 9-stage high glucose clamp test was done before and 48 hours,14 days after taking empagliflozin to quantitatively evaluate the effect of FPG reduction on islet β-cell function. The results showed that FPG concentration decreased only in IFG subjects from(110 ± 2)to(103 ± 3)mg/dl(P<0.01)after taking empagliflozin for 14 days,but the FPG remained unchanged[(95 ± 2) to(94 ± 2) mg/dl] in NFG subjects. The incremental area under the plasma C-peptide concentration curve during the hyperglycemic clamp increased by 22% ± 4% and 23% ± 4% in IFG subjects after 48 hours and 14 days,respectively(P<0.01);the plasma C-peptide response remained unchanged in NFG subjects. The insulin secretion/insulin sensitivity(disposition) index increased significantly in IFG,but not in NFG subjects. In conclusion,empagliflozin only reduces the FPG concentration and improves β-cell function in IFG.